Farmacia italiana online: acquisto cialis in Italia e Roma senza ricetta.

Erectile dysfunction drugs market (viagra, cialis, levitra/staxyn, stendra/spedra, zydena, muse, mvix and helleva) - global industry analysis, size, share, growth, trends and forecast, 2013 - 2019

Erectile Dysfunction Drugs Market (Viagra, Cialis,Levitra/Staxyn, Stendra/Spedra, Zydena, MUSE,Mvix and Helleva) - Global Industry Analysis, Size,Share, Growth, Trends and Forecast, 2013 - 2019 Phone: +44 20 8123 2220Fax: +44 207 900 3970office@marketpublishers.com Phone: +44 20 8123 2220http://marketpublishers.com Erectile Dysfunction Drugs Market (Viagra, Cialis, Levitra/Staxyn,Stendra/Spedra, Zydena, MUSE, Mvix and Helleva) - Global IndustryAnalysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019 This report studies the global erectile dysfunction drugs market with a major focus on the branded drugswhich include Viagra (sildenafil citrate), Cialis (tadalafil), Levitra/Staxyn (vardenafil), Stendra/Spedra(avanafil), Zydena (udenafil) and others such as MUSE (Medicated Urethral System for Erections), Mvixand Helleva. Pipeline analysis for drugs namely, Vitaros (alprostadil), Uprima (apomorphine) and fewothers have also been included in the report. Market size and forecasts for the period 2010 – 2019 havebeen provided for each of the drugs, in terms of USD million, considering historical data for 2010 and 2011,and base year as 2012. The % compounded annual growth rate (CAGR) for each market segment for theforecast period 2013 - 2019 has also been provided along with market size estimations.
Geographically, the market has been segmented into four regions, namely, North America, Europe,Asia-Pacific, and Rest of the World (RoW). The respective market size and forecast till 2019 for eachregion has also been presented in the report along with the CAGR. In addition, the market overview sectionof the report provides a qualitative assessment of the market dynamics wherein the drivers, restraints, andopportunities along with market attractiveness and Porter’s Five Forces analysis have been studied.
The competitive landscape section includes market share analysis of the leading players in the brandeddrugs market for erectile dysfunction treatment, in terms of percentage share in the year 2012. Some of themajor players profiled in this report include Pfizer, Inc., Eli Lilly and Co., Bayer AG, Dong-A PharmaceuticalCo. Ltd., and Vivus, Inc.
Table of Content
CHAPTER 1 INTRODUCTION
1.1 Report Description1.2 Market Segmentation1.3 Research Methodology1.4 List of Abbreviations CHAPTER 2 EXECUTIVE SUMMARY
CHAPTER 3 MARKET OVERVIEW
3.1 Introduction to Erectile Dysfunction3.2 Current Market Trends and Future Outlook 3.2.1 Impact of Generics 3.2.2 Key Patent Expirations 3.2.3 Ongoing Clinical Trials in the U.S. for ED Treatment (Phase III)3.3 Types of Treatments for ED 3.3.1 Phosphodiesterase Type 5 Inhibitors (PDE 5 Inhibitors) 3.3.2 Localized Therapy 3.3.3 Testosterone Replacement Therapy 3.3.4 Vacuum Constriction Devices 3.3.5 Surgery (Penile Implants and Vascular Surgery) Phone: +44 20 8123 2220http://marketpublishers.com 3.3.6 Alternative Medicines (Yohimbine and Other Herb and Dietary Supplements)3.4 Market Drivers 3.4.1 Increase in Elderly Population 3.4.2 Increasing Global Incidence of Various Diseases and Growing Preference Towards SedentaryLifestyle 3.4.3 Increase in Awareness and Patient Education3.5 Market Restraints 3.5.1 Prevalence of Sexually Transmitted Diseases with ED Drug Users 3.5.2 Narrowing of Insurance Coverage for Erectile Dysfunction Treatment 3.5.3 Growing Threat from Counterfeit Drugs3.6 Market Opportunities 3.6.1 Novel Molecule Combinations and Drug Delivery Techniques are Expected to Become a RisingOpportunity 3.6.2 Generics - A Growing Global Opportunity3.7 Porter’s Five Forces Analysis: Global Erectile Dysfunction Drugs Market 3.7.1 Bargaining Power of Suppliers 3.7.2 Bargaining Power of Buyers 3.7.3 Threat of Substitutes 3.7.4 Threat of New Entrants 3.7.5 Competitive Rivalry3.8 Market Attractiveness Analysis: Global Erectile Dysfunction Drugs Market, By Geography (2015) CHAPTER 4 GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET REVENUE, BY BRAND,
2011-2019 (USD MILLION)

4.1 Market Overview 4.1.1 Mechanism of Action 4.1.2 Characteristics of Major Phosphodiesterase Type 5 Inhibitors4.2 Viagra (Sildenafil Citrate) 4.2.1 Introduction 4.2.2 Global Viagra Market for Erectile Dysfunction Treatment, 2010 – 2019 (USD Million) 4.2.3 Patent Expiration and Regulatory Scenario 4.2.3.1 The U.S. Market 4.2.3.2 International Market 4.2.4 Past & Current Market Scenario 4.2.5 Global Viagra Market for Erectile Dysfunction Treatment, 2010 – 2014 (USD Million) 4.2.6 Future Market Scenario 4.2.7 Global Viagra Market for Erectile Dysfunction Treatment, 2015 – 2019 (USD Million)4.3 Cialis (Tadalafil) 4.3.1 Introduction 4.3.2 Global Cialis Market for Erectile Dysfunction Treatment, 2010 – 2019 (USD Million) 4.3.3 Patent and Regulatory Scenario 4.3.4 Current Market Scenario and Patent Expiry Effect 4.3.5 Global Cialis Market for Erectile Dysfunction Treatment, 2010 – 2014 (USD Million) 4.3.6 Future Market Scenario 4.3.7 Global Cialis Market for Erectile Dysfunction Treatment, 2015 – 2019 (USD Million)4.4 Levitra/Staxyn (Vardenafil) 4.4.1 Introduction 4.4.2 Global Levitra/Staxyn Market for Erectile Dysfunction Treatment, 2010 – 2019 (USD Million) 4.4.3 Patent and Regulatory Scenario 4.4.4 Current and Future Market Scenario 4.4.5 Global Levitra/Staxyn Market For Erectile Dysfunction Treatment, 2010 – 2014 (USD Million) 4.4.6 Global Levitra/Staxyn Market for Erectile Dysfunction Treatment, 2015 – 2019 (USD Million)4.5 Stendra/Spedra (Avanafil) 4.5.1 Introduction Phone: +44 20 8123 2220http://marketpublishers.com 4.5.2 Future Market Scenario 4.5.3 Global Stendra/Spedra Market for Erectile Dysfunction Treatment, 2015 – 2019 (USD Million)4.6 Zydena (Udenafil) 4.6.1 Introduction 4.6.2 Global Zydena Market for Erectile Dysfunction Treatment, 2010 – 2019 (USD Million) 4.6.3 Current Market Scenario 4.6.4 Global Zydena Market for Erectile Dysfunction Treatment, 2010 – 2014 (USD Million) 4.6.5 Future Market Scenario 4.6.6 Global Zydena Market for Erectile Dysfunction Treatment, 2015 – 2019 (USD Million)4.7 MUSE (Medicated Urethral System for Erection) 4.7.1 Patent and Regulatory Scenario4.8 Mvix (Mirodenafil)4.9 Helleva (Lodenafil Carbonate) CHAPTER 5 GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET, PIPELINE ANALYSIS
5.1 Overview5.2 Vitaros (Alprostadil) 5.2.1 Global Vitaros Market for Erectile Dysfunction Treatment, 2014 – 2019 (USD Million)5.3 Uprima (Apomorphine)5.4 Others (Topiglan, Melanocortin Activators, Gene Therapy) 5.4.1 Topiglan 5.4.2 Melanocortin Activators 5.4.3 Gene Therapy CHAPTER 6 GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET, BY GEOGRAPHY
6.1 Overview 6.1.1 Global Erectile Dysfunction Drugs Market Revenue, By Geography, 2010 – 2019 (USD Million) 6.1.2 Comparative Analysis: Global Erectile Dysfunction Drugs Market, By Geography, 2012 & 2019(Value %)6.2 North America 6.2.1 North America Erectile Dysfunction Drugs Market, 2010 – 2014 (USD Million) 6.2.2 North America Erectile Dysfunction Drugs Market, 2015 - 2019 (USD Million)6.3 Europe 6.3.1 Europe Erectile Dysfunction Drugs Market, 2010 – 2014 (USD Million) 6.3.2 Europe Erectile Dysfunction Drugs Market, 2015 - 2019 (USD Million)6.4 Asia-Pacific 6.4.1 Asia-Pacific Erectile Dysfunction Drugs Market, 2010 – 2014 (USD Million) 6.4.2 Asia-Pacific Erectile Dysfunction Drugs Market, 2015 - 2019 (USD Million)6.5 Rest of the World (Row) 6.5.1 Rest of the World (Row) Erectile Dysfunction Drugs Market, 2010 – 2014 (USD Million) 6.5.2 Rest of the World (Row) Erectile Dysfunction Drugs Market, 2015 – 2019 (USD Million) CHAPTER 7 COMPETITIVE LANDSCAPE
7.1 Market Share Analysis: Global Erectile Dysfunction Drugs Market, 2012 (%) 7.1.1 Methodology 7.1.2 Analysis CHAPTER 8 RECOMMENDATIONS
8.1 Novel Drug Formulations and Genericization owing to Patent Expiration of well recognized ED Drugs8.2 Mergers and Acquisitions to Strengthen Market Presence8.3 Cost Containment Measures Phone: +44 20 8123 2220http://marketpublishers.com CHAPTER 9 COMPANY PROFILES
9.1 Apricus Biosciences, Inc.
9.1.1 Company Overview 9.1.2 Business Strategies 9.1.3 Financial Overview 9.1.4 Product Portfolio 9.1.5 Recent Developments9.2 Bayer AG 9.2.1 Company Overview 9.2.2 Business Strategies 9.2.3 Financial Overview 9.2.4 Product Portfolio 9.2.5 Recent Developments9.3 Cristalia Produtos Quimicos Farmaceuticos Ltda.
9.3.1 Company Overview 9.3.2 Business Strategies 9.3.3 Product Portfolio 9.3.4 Recent Developments9.4 Dong-A Pharmaceutical Co. Ltd.
9.4.1 Company Overview 9.4.2 Business Strategies 9.4.3 Financial Overview 9.4.4 Product Portfolio 9.4.5 Recent Developments9.5 Eli Lilly And Company 9.5.1 Company Overview 9.5.2 Business Strategies 9.5.3 Financial Overview 9.5.4 Product Portfolio 9.5.5 Recent Developments9.6 Meda Pharmaceuticals, Inc.
9.6.1 Company Overview 9.6.2 Business Strategies 9.6.3 Product Portfolio 9.6.4 Recent Developments9.7 Pfizer, Inc.
9.7.1 Company Overview 9.7.2 Business Strategies 9.7.3 Financial Overview 9.7.4 Product Portfolio 9.7.5 Recent Developments9.8 S.K. Chemicals Co. Ltd.
9.8.1 Company Overview 9.8.2 Business Strategies 9.8.3 Financial Overview 9.8.4 Product Portfolio 9.8.5 Recent Developments9.9 Vivus, Inc.
9.9.1 Company Overview 9.9.2 Business Strategies 9.9.3 Financial Overview 9.9.4 Product Portfolio 9.9.5 Recent Developments Phone: +44 20 8123 2220http://marketpublishers.com LIST OF FIGURES
FIG. 1 Erectile Dysfunction Drugs Market SegmentationFIG. 2 Global Erectile Dysfunction Drugs Market Revenue, 2010 - 2019 (USD Million)FIG. 3 Porter’s Five Forces Analysis: Global Erectile Dysfunction Drugs MarketFIG. 4 Market Attractiveness Analysis: Global Erectile Dysfunction Drugs Market, By Geography (2015)FIG. 5 PPDE 5 Inhibitors: Mechanism of ActionFIG. 6 Global Viagra Market For Erectile Dysfunction Treatment, 2010 – 2019 (USD Million)FIG. 7 Global Viagra Market For Erectile Dysfunction Treatment, 2010 – 2014 (USD Million)FIG. 8 Global Viagra Market For Erectile Dysfunction Treatment, 2015 – 2019 (USD Million)FIG. 9 Global Cialis Market For Erectile Dysfunction Treatment, 2010 – 2019 (USD Million)FIG. 10 Global Cialis Market For Erectile Dysfunction Treatment, 2010 – 2014 (USD Million)FIG. 11 Global Cialis Market For Erectile Dysfunction Treatment, 2015 – 2019 (USD Million)FIG. 12 Global Levitra/Staxyn Market For Erectile Dysfunction Treatment, 2010 – 2019 (USD Million)FIG. 13 Global Levitra/Staxyn Market For Erectile Dysfunction Treatment, 2010 – 2014 (USD Million)FIG. 14 Global Levitra/Staxyn Market For Erectile Dysfunction Treatment, 2015 – 2019 (USD Million)FIG. 15 Global Stendra/Spedra Market For Erectile Dysfunction Treatment, 2015 – 2019 (USD Million)FIG. 16 Global Zydena Market For Erectile Dysfunction Treatment, 2010 – 2019 (USD Million)FIG. 17 Global Zydena Market For Erectile Dysfunction Treatment, 2010 – 2014 (USD Million)FIG. 18 Global Zydena Market For Erectile Dysfunction Treatment, 2015 – 2019 (USD Million)FIG. 19 Global Vitaros Market For Erectile Dysfunction Treatment, 2014 – 2019 (USD Million)FIG. 20 Comparative Analysis: Global Erectile Dysfunction Drugs Market, By Geography, 2012 & 2019(Value %)FIG. 21 North America Erectile Dysfunction Drugs Market, 2010 – 2014 (USD Million)FIG. 22 North America Erectile Dysfunction Drugs Market, 2015 - 2019 (USD Million)FIG. 23 Europe Erectile Dysfunction Drugs Market, 2010 – 2014 (USD Million)FIG. 24 Europe Erectile Dysfunction Drugs Market, 2015 - 2019 (USD Million)FIG. 25 Asia-Pacific Erectile Dysfunction Drugs Market, 2010 – 2014 (USD Million)FIG. 26 Asia-Pacific Erectile Dysfunction Drugs Market, 2015 - 2019 (USD Million)FIG. 27 Rest Of The World (Row) Erectile Dysfunction Drugs Market, 2010 – 2014 (USD Million)FIG. 28 Rest Of The World (Row) Erectile Dysfunction Drugs Market, 2015 – 2019 (USD Million)FIG. 29 Market Share By Key Players: Branded Formulations For Erectile Dysfunction Treatment, 2012 (%)FIG. 30 Apricus Biosciences, Inc.: Annual Revenue, 2010 – 2012 (USD Million)FIG. 31 Bayer AG: Annual Revenue, 2010 – 2012 (USD Million) (1 Euro = 1.35 USD)FIG. 32 Dong-A Pharmaceutical Co. Ltd.: Annual Revenue, 2010 – 2012 (USD Million) (1 KRW = 0.0093USD)FIG. 33 Eli Lilly & Co.: Annual Revenue, 2010 – 2012 (USD Million)FIG. 34 Pfizer, Inc.: Annual Revenue, 2010 – 2012 (USD Million)FIG. 35 S. K. Chemicals Co. Ltd.: Annual Revenue, 2010 – 2012 (USD Million) (1 KRW = 0.0093 USD) LIST OF TABLES
TABLE 1 Market Snapshot: Global Erectile Dysfunction Drugs MarketTABLE 2 Causes Of Erectile DysfunctionTABLE 3 Ongoing Clinical Trials In The U.S. For ED Treatment (Phase III)TABLE 4 Causes Of ED: Classes Of Drugs Used To Treat Chronic DiseasesTABLE 5 Global Erectile Dysfunction Drugs, 2010 – 2014 (USD Million)TABLE 6 Global Erectile Dysfunction Drugs, 2015 – 2019 (USD Million)TABLE 7 Characteristics Of PDE 5 Inhibitor Class Of Erectile Dysfunction DrugsTABLE 8 Global Erectile Dysfunction Drugs Market Revenue, By Geography, 2010 – 2014 (USD Million)TABLE 9 Global Erectile Dysfunction Drugs Market Revenue, By Geography, 2015 – 2019 (USD Million) Phone: +44 20 8123 2220http://marketpublishers.com Erectile Dysfunction Drugs Market (Viagra, Cialis, Levitra/Staxyn, Stendra/Spedra, Zydena, MUSE, Mvix and Helleva) - Global Industry Analysis, Size, Share, Growth, US$ 4,795.00 (Single User License / Electronic Delivery) If you want to order Corporate License or Hard Copy, please, contact our Customer Service: office@marketpublishers.com To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click 'BUY NOW' button To pay by Wire Transfer, please, fill in your contact details in the form below: Customer Signature _______________________________________ Please, note that by ordering from MarketPublisher.com you are agreeing to our Terms & Conditions at To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

Source: http://pdf.marketpublishers.com/transparency/erectile-dysfunction-drugs-market-viagra-cialis-levitrastaxyn-stendraspedra-zydena-muse-mvix-n-helleva.pdf

wordsndesign.co.nz

Are homosexuals born that way? For a comprehensive account of the contribution of genes, hormones, brain microstructure, intersex conditions and environment to homosexu-ality see My Genes Made Me Do It! - a scientific look at Sexual Orientation, Neil and Briar Whitehead, Huntington House, 1999. Researchers have tried for decades to identify a biomedical basis to homosexuality, but haven’

s127133077.onlinehome.us

1. Pollock A, Baer G, Pomeroy V, Langhorne P. Physiotherapy treatment ap- 10. Khadilkar A, Phillips K, Jean N, Lamothe C, Milne S, Sarnecka J. Ottawa Panel proaches for the recovery of postural control and lower limb function followingevidence-based clinical practice guidelines for post-stroke rehabilitation. Top Stroke stroke. Cochrane Database Syst Rev . 2003;(2):CD001920. 2. Pomero

Copyright © 2010-2014 Pdf Pills Composition